Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions

Journal of Neuroscience Research

Volumn 54, Issue 1, 1998, Pages 1-6

  Pasinetti, Giulio Maria ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cyclooxygenase; Inflammation; NSAIDs; Oxidative stress

Indexed keywords

GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRAIN PROTECTION; COMPLEMENT ACTIVATION; DRUG INDICATION; DRUG MECHANISM; ENZYME INHIBITION; INFLAMMATION; NERVE DEGENERATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; OXIDATIVE STRESS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0032190264     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19981001)54:1<1::AID-JNR1>3.0.CO;2-M     Document Type: Review

References (57)

1. Adams J, Collaço-Moraes Y, de Belleroche J (1996): Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 66:6-13.
2. Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T, Davis KL (1996a): A pilot study of prednisone in Alzheimer's disease. Dementia 7:201-206.
3. Aisen PS, Marin D, Fusco M, Baruch B, Ryan T, Davis KL (1996b): A pilot study of colchicine in Alzheimer's disease. Alzheimer's Res 2:153-156.
4. Aisen PS (1997): Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies. Gerontology 43:143-149.
5. Aisen PS, Davis KL (1994): Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am J Psychiatry 151:1105-1113.
6. Aisen PS, Davis KL (1997): Anti-inflammatory therapy for Alzheimer's disease: a status report. Int J Geriatr Psychopharmacol 1:2-5.
7. Aisen PS, Pasinetti GM (1998): Glucocorticoids in Alzheimer's disease: the story so far. Drugs and Aging 12:1-6.
8. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler NMB, Hofman A (1995): Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology 45:1441-1445.
9. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC (1994): Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44:227-232.
10. Breitner JCS, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM (1995): Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16:523-530.
11. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MBA, Mucke L (1993): Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 90:10061-10065.
12. Cao C, Matsumura K, Yamagata K, Watanabe Y (1995): Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. Brain Res 697:187-196.
13. Chang JW, Coleman PD, O'Banion MK (1996): Prostaglandin G/H synthase-2 (cyclooxygenase-2): mRNA expression is decreased in Alzheimer's disease. Neurobiol Aging 17:801-808.
14. Clements PJ, Paulus HE (1993): Nonsteroidal anti-inflammatory drugs (NSAIDs). In: Kelley WN, Harris ED, Jr., Ruddy S, Sledge CB (eds): "Textbook of Rheumatology." Philadelphia; W.B. Saunders Company, pp 700-730.
15. Fagarasan MO, Aisen PS (1996): Il-1 and anti-inflammatory drugs modulate Aβ cytotoxicity in PC12 cells. Brain Res 723:231-234.
16. Gearing M, Mori H, Mirra SS (1996): ABeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 39:395-399.
17. Halliwell B, Gutteridge JMC (1989): Free Radicals in Biology and Medicine. Oxford; Clarendon Press.
18. Hewett SJ, Hewett JA (1997): COX-2 contributes to NMDA-induced neuronal death in cortical cell cultures. Society for Neuroscience Abstracts 23:1666 (Abstract).
19. Ho L, Osaka H, Aisen P, Pasinetti GM (1998): Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J Neuroimmunol 1:142-149.
20. Iwamoto N, Kobayashi K, Kosaka K (1989): The formation of prostaglandins in the post-mortem cerebral cortex of Alzheimertype dementia patients. J Neurol 236:80-84.
21. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P (1996): COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93:2317-2321.
22. Kimura H, Okamoto K, Sakai Y (1985): Modulatory effects of prostaglandins D2, E2 and F2α on the postsynaptic action of inhibitory and excitatory amino acids in cerebellar Purkinje cell dendrites in vitro. Brain Res 330:235-244.
23. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991): TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue. J Biol Chem 266:12866-12872.
24. Lehtonen JYA, Holopainen JM, Kinnunen PKJ (1996): Activation of phospholipase A2 by amyloid Beta-peptides in vitro. Biochemistry 35:9407-9414.
25. London JA, Biegel D, Pachter JS (1996): Neurocytopathic effects of Beta-amyloid-stimulated monocytes: A potential mechanism for central nervous system damage in Alzheimer disease. Proc Natl Acad Sci USA 93:4147-4152.
26. Lu X, Xie W, Reed D, Bradshaw WS, Simmons DL (1996): Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA 92:7961-7965.
27. Lucca U, Tettamanti M, Forloni G, Spagnoli A (1994): Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 36:854-856.
28. Mattson MP, Rydel RE, Lieberburg I, Smith-Swintosky VL (1993): Altered calcium signaling and neuronal injury: Stroke and Alzheimer's disease as examples. Ann NY Acad Sci 679:1-21.
29. McGeer PL, Itagaki S, Tago H, McGeer EG (1987): Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 79:195-200.
30. McGeer PL, McGeer E, Rogers J, Sibley J (1990): Anti-inflammatory drugs and Alzheimer disease. Lancet 335:1037.
31. McGeer PL, McGeer EG, Kawamata T, Yamada T, Akiyama H (1991): Reactions of the immune system in chronic degenerative neurological diseases. Can J Neurol Sci 18:376-379.
32. McGeer PL, Schulzer M, McGeer EG (1996): Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 47:425-432.
33. Minghetti L, Polazzi E, Nicolini A, Creminon C, Levi G (1997): Up-regulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non-steroidal anti-inflammatory drug. Eur J Neurosci 9:934-940.
34. Morimoto K, Oda T, Yamada N, Kaneko I (1997): Co-injections of β-amyloid protein and ibotenic acid produces neurotoxicity in rat hippocampus. Society for Neuroscience Abstracts 23:1628 (Abstract).
35. Murakami M, Nakatani Y, Atsumi G, Inoue K, Kudo I (1997): Regulatory functions of phospholipase A2. Crit Rev Immunol 17:225-283.
36. Murphy RC (1989): Biosynthesis and metabolism. In: Watkins WD (ed): "Prostaglandins in Clinical Practice." New York; Raven Press, pp 1-20.
37. O'Banion MK, Winn VD, Young DA (1992): cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 89:4888-4892.
38. Oda T, Lehrer-Graiwer J, Finch CE, Pasinetti GM (1995): Complement and β-amyloid (aβ): neurotoxicity in vitro: a model for Alzheimer disease. Alzheimer's Res 1:29-34.
39. Oka A, Takashima S (1997): Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport 8:1161-1164.
40. Olney JW, Wozniak DF, Farber NB (1997): Excitotoxic neurodegeneration in Alzheimer disease - New hypothesis and new therapeutic strategies. Arch Neurol 54:1234-1240.
41. Pasinetti GM (1996): Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: The role of the complement system. Neurobiol Aging 17:707-716.
42. Pasinetti GM and Aisen PS (1998): Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87:319-324.
43. Pike CJ, Ramezan-Arab N, Cotman CW (1997): Beta-amyloid neurotoxicity in vitro: Evidence of oxidative stress but not protection by antioxidants. J Neurochem 69:1601-1611.
44. Planas AM, Soriano MA, Rodríguez-Farré E, Ferrer I (1995): Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain. Neurosci Lett 200:187-190.
45. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J (1995): Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45:51-55.
46. Rogers J, Luber-Narod J, Styren SD, Civin WH (1988): Expression of immune-system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9:339-349.
47. Rogers J, Civin WH, Styren SD, McGeer PL (1992): Immune-related mechanisms of Alzheimer's disease pathogenesis. In: Khachaturian ZS, Blass JB (eds): "Alzheimer's Disease: New Treatment Strategies." New York; Marcel Dekker, Inc., pp 147-163.
48. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F (1993): Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609-1611.
49. Singh IN, Sorrentino G, Sitar DS, Kanfer JN (1997): Indomethacin and nordihydroguaiaretic acid inhibition of amyloid Beta protein (25-35): activation of phospholipases A2 and D of LA-N-2 cells. Neurosci Lett 222:5-8.
50. Smith WL, Garavito RM, DeWitt DL (1996): Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271:33157-33160.
51. Stewart WF, Kawas C, Corrada M, Metter EJ (1997): Risk of Alzheimer's disease and duration of NSAID use. Neurology 48:626-632.
52. Subbarao KV, Richardson JS, Ang LC (1990): Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 55:342-345.
53. Tocco G, Freire O, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GM (1997): Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp Neurol 144:339-349.
54. Tsujii M, DuBois RN (1996): Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501.
55. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J (1997): Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 18:415-421.
56. Wong PT-H, McGeer PL, McGeer EG (1992): Decreased prostaglandin synthesis in postmortem cerebral cortex from patients with Alzheimer's disease. Neurochem Int 21:197-202.
57. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF (1993): Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11:371-386.